Trade PTC Therapeutics Inc - PTCT CFD

Add to favourite

56.93

0.12%

0.12

Low: 55.95

High: 57.15

Market Trading Hours* (UTC) Opens on Tuesday at 13:30

Mon - Fri: 13:30 - 20:00

Summary
Historical Data

Trading сonditions

Spread

0.12

Long position overnight fee

-0.023374%

Short position overnight fee

0.001151%

Overnight fee time

21:00 (UTC)

Min traded quantity

0.1

Currency

USD

Margin

50.00%

Stock exchange

United States of America

Commission on trade

Key Stats

Prev. Close	57
Open	57.09
1-Year Change	96.52%
Day's Range	55.95 - 57.15

Last Week
Last Month
Last Year
Last two Years
Max

Daily
Weekly
Monthly

Date	Close	Change	Change (%)	Open	High	Low
Mar 24, 2025	56.93	-0.47	-0.82%	57.40	57.40	55.54
Mar 21, 2025	57.00	1.23	2.21%	55.77	57.20	55.36
Mar 20, 2025	56.57	0.55	0.98%	56.02	57.47	56.02
Mar 19, 2025	56.89	1.94	3.53%	54.95	57.30	54.95
Mar 18, 2025	55.42	-1.03	-1.82%	56.45	56.45	54.95
Mar 17, 2025	57.09	3.19	5.92%	53.90	58.22	53.90
Mar 14, 2025	54.44	1.40	2.64%	53.04	55.43	53.04
Mar 13, 2025	52.71	0.21	0.40%	52.50	54.53	52.50
Mar 12, 2025	53.50	0.94	1.79%	52.56	53.66	52.07
Mar 11, 2025	52.54	-0.34	-0.64%	52.88	53.01	50.65
Mar 10, 2025	52.39	0.51	0.98%	51.88	53.53	50.71
Mar 7, 2025	52.53	0.13	0.25%	52.40	53.61	51.56
Mar 6, 2025	52.72	1.75	3.43%	50.97	52.75	50.02
Mar 5, 2025	51.86	0.32	0.62%	51.54	52.35	50.41
Mar 4, 2025	51.72	-0.45	-0.86%	52.17	52.50	49.53
Mar 3, 2025	52.76	-1.69	-3.10%	54.45	55.40	52.45
Feb 28, 2025	55.19	10.89	24.58%	44.30	55.29	44.26
Feb 27, 2025	50.46	-0.01	-0.02%	50.47	52.44	50.40
Feb 26, 2025	50.88	0.41	0.81%	50.47	51.54	49.52
Feb 25, 2025	50.28	0.58	1.17%	49.70	50.45	48.46

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission

Leverage

2:1

20
100
500
1000
10000

Investment

Trade size (Leverage x Investement):

Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

PTC Therapeutics Company profile

About PTC Therapeutics, Inc.

PTC Therapeutics, Inc. is a science-driven global biopharmaceutical company. The Company is focused on the discovery, development and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. The Company's portfolio pipeline includes several commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focused on the development of new treatments for multiple therapeutic areas, including rare diseases and oncology. The Company has two products, Translarna (ataluren) and Emflaza (deflazacort), for the treatment of Duchenne muscular dystrophy (DMD). It has a pipeline of gene therapy product candidates for rare monogenic diseases that affect the central nervous system (CNS), including PTC-AADC for the treatment of Aromatic L-Amino Acid Decarboxylase (AADC).

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, PTC Therapeutics, Inc. revenues increased 41% to $538.6M. Net loss increased 20% to $523.9M. Revenues reflect United States segment increase of 59% to $297M, Non-US segment increase of 24% to $241.6M. Higher net loss reflects Non-GAAP research and development increase of 11% to $487.1M (expense), Interest expense, net - Balancing value increase of 52% to $85.1M (expense).